| Age (years), mean ± SD (range) |
68.3 ± 2.8 (39-87) |
| Sex, male, n (%) |
8 (32.0) |
| BMI (kg/m2), median (IQR) |
19.0 ± 2.8 |
| ECOG PS, n (%) |
|
| 4 |
3 (12.0) |
| 3 |
14 (56.0) |
| 2 |
5 (20.0) |
| 1 |
3 (12.0) |
| 0 |
0 (0.0) |
| Primary cancer site, n (%) |
|
| Colon |
5 (20.0) |
| Pancreas |
4 (16.0) |
| Breast |
3 (12.0) |
| Uterine |
3 (12.0) |
| Bone |
2 (8.0) |
| Lung |
2 (8.0) |
| Others |
6 (24.0) |
| Metastases, n (%) (including duplicate answers) |
|
| Lung |
11 (44.0) |
| Bone |
9 (36.0) |
| Liver |
9 (36.0) |
| Lymph node |
5 (20.0) |
| Peritoneal |
4 (16.0) |
| Muscle |
3 (12.0) |
| Brain |
2 (8.0) |
| Pancreas |
2 (8.0) |
| Subcutaneous tissue |
2 (8.0) |
| Others |
8 (32.0) |
| None |
1 (4.0) |
| Type of pain, n (%) (including duplicate answers) |
|
| Somatic pain |
17 (68.0) |
| Visceral pain |
13 (52.0) |
| Neuropathic pain |
21 (84.0) |
| Opioids before switching to methadone, n (%) |
|
| Fentanyl |
8 (32.0) |
| Oxycodone |
8 (32.0) |
| Tapentadol |
5 (20.0) |
| Morphine |
2 (8.0) |
| Tramadol |
1 (4.0) |
| Naive |
1 (4.0) |
| MEDD (mg/day), mean ± SD (range) |
135.4 ± 118.9 (0-500) |
| Heart disease, n (%) |
8 (32.0) |
| Concomitant medications (including duplicate answers), n (%) |
| Acetaminophen |
8 (32.0) |
| NSAIDs |
| Loxoprofen |
7 (28.0) |
| Celecoxib |
5 (20.0) |
| Diclofenac |
1 (4.0) |
| Flurbiprofen |
1 (4.0) |
| Meloxicam |
1 (4.0) |
| None |
12 (48.0) |
| Adjuvant analgesics |
|
| Corticosteroids |
12 (48.0) |
| SNRI |
3 (12.0) |
| Anti-arrhythmic drugs |
2 (8.0) |
| Anticonvulsants |
2 (8.0) |
| None |
11 (44.0) |
